Jeffrey James Jackson

6PUBLICATIONS
13CO-AUTHORS
Cheminformatics and quantitative structure-activity relationshipsBiomolecular modelling and designMolecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 29, 2026
Composite Peak Scoring for Improved Charged Aerosol Detector-Based Universal Quantification of Drug Libraries.

|Nov 21, 2023
Imidazolone as an Amide Bioisostere in the Development of β-1,3-N-Acetylglucosaminyltransferase 2 (B3GNT2) Inhibitors.

Jeffrey J Jackson, Aaron C Siegmund, Wen-Ju Bai

|Sep 20, 2022
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy.

Jeffrey J Jackson, Grant M Shibuya, Buvana Ravishankar

|Jan 13, 2022
EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22.

Aparna Jorapur, Lisa A Marshall, Scott Jacobson

|Jul 16, 2020
Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors.

Omar Robles, Jeffrey J Jackson, Lisa Marshall

|Jul 02, 2019
Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment.

Jeffrey J Jackson, John M Ketcham, Ashkaan Younai

Pageof 1

Frequent Collaborators

1 joint publications

Omar Robles

1 joint publications

Valentin Baloche

1 joint publications

Pierre Busson

1 joint publications

Dirk G Brockstedt